A Phase 1 Randomized, Prospective, Double-Masked, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon in Subjects Following Bilateral Photorefractive Keratectomy (PRK) for the Correction of Mild to Moderate Myopia.
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2018
At a glance
- Drugs CODA 001 (Primary)
- Indications Myopia
- Focus Adverse reactions
- Sponsors OcuNexus Therapeutics
- 25 Jul 2018 According to Ocunexus Therapeutics website, CoDa Therapeutics is now called OcuNexus Therapeutics.
- 06 Dec 2014 New trial record